What does this video actually claim?
@yiriamg shares her experience after one month on Wegovy (semaglutide), saying it's helping her with a "big change" and boosting her confidence. She uses hashtags suggesting weight loss but doesn't make specific medical claims about results or side effects.
The video is personal testimony rather than medical advice. She mentions being "grateful" for the medication's assistance, which suggests she's experiencing positive effects, though she doesn't specify weight loss numbers or other concrete outcomes.
Her approach is relatively cautious compared to many GLP-1 content creators who make bold claims about rapid results.
Is one month enough time to see real results?
Yes, but you're still in the early stages. The STEP 1 trial (Wilding et al., NEJM, 2021) showed average weight loss of 2.9kg (6.4 pounds) at week 4 with semaglutide 2.4mg. Most patients don't reach the maintenance dose until week 17.
Wegovy starts at 0.25mg weekly and increases every four weeks. At one month, you're likely still on the 0.5mg dose, which is primarily for tolerance building rather than maximum efficacy.
The confidence boost @yiriamg mentions could be real. GLP-1 agonists reduce food noise and cravings within days to weeks of starting treatment. That psychological relief often comes before significant weight loss shows on the scale.
What did she get right about the timeline?
Her "slowly but surely" framing is spot-on. The STEP trials showed that semaglutide's weight loss curve is gradual, with most benefits accumulating over 68 weeks, not weeks.
She also correctly positions Wegovy as an "assist" rather than a magic solution. The medication works by mimicking GLP-1 hormones that regulate appetite and glucose, but lifestyle changes remain necessary for optimal results.
@yiriamg avoids the common mistake of promising dramatic overnight transformations that flood GLP-1 TikTok content.
What should you actually know about starting Wegovy?
The first month is about finding your tolerance, not seeing your final results. About 74% of patients in STEP 1 experienced gastrointestinal side effects, mostly nausea, which typically peaks during dose escalations.
Real efficacy data comes from longer timeframes. At 68 weeks, patients lost an average of 14.9% body weight on 2.4mg semaglutide versus 2.4% on placebo. The 5% weight loss threshold was reached by 83.5% of semaglutide patients.
Insurance coverage remains challenging. Wegovy costs around $1,300 monthly without insurance, and many plans exclude weight management medications. The shortage issues that plagued 2022-2023 have largely resolved, but supply can still be inconsistent.